- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
Munich and Ann Arbor, Michigan (ots/PRNewswire) - - Application is based on results of a robust development programme, which demonstrated that bempedoic acid was well tolerated and efficacious for chronic use - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...
Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...
Munich (ots/PRNewswire) - An independent expert jury has selected Airbus for the Innovation Award 2018. The jury concluded that the future of urban air mobility can only be addressed by comprehensive concepts rather than by individual aircraft. (Logo: https://mma.prnewswire.com/media/787725/MPC_Logo.jpg ) (Logo: ...
5GAA - 5G Automotive Association e.V.
Munich (ots) - As regulators worldwide are looking into future rules for connected cars technologies, the 5G Automotive Association has conducted tests to compare the performance of 802.11p/DSRC (known in Europe as ITS-G5) and Cellular V2X PC5 radio technologies in delivering V2V (Vehicle-To-Vehicle) safety ...
Schweizerischer Nationalfonds / Fonds national suisse
European Society for Medical Oncology (ESMO)
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF ?-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; ...
Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
Munich (ots/PRNewswire) - - Hokusai-VTE CANCER study showed that oral edoxaban is non-inferior to subcutaneous injectable dalteparin, for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding in cancer-associated VTE - This analysis provides benefit/risk assessment in different types of ...
DGAP-News: EDAG Engineering Group AG / Key word(s): Change of Personnel EDAG Engineering Group AG: Dr. Philippe A. Weber elected interim Chairman of the Board, Extraordinary General Meeting on August 21th 26.07.2018 / 10:13 The issuer is solely responsible for the content of this announcement. ...
DGAP-News: BB BIOTECH AG / Key word(s): Half Year Results BB Biotech shares hold steady in the second quarter (news with additional features) 20.07.2018 / 07:00 The issuer is solely responsible for the content of this announcement. Media release as of July 20, 2018 Interim report of BB Biotech AG as of June 30, 2018 BB Biotech shares hold steady in the second quarter - Substantial portfolio adjustments, new investments ...
DGAP-Ad-hoc: EDAG Engineering Group AG / Key word(s): Change of Personnel EDAG Engineering Group AG: Changes in the Board of Directors 18-Jul-2018 / 16:12 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this ...
DGAP-Ad-hoc: EDAG Engineering Group AG / Key word(s): Change of Personnel EDAG Engineering Group AG: Changes in the board 18-Jul-2018 / 11:31 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 705711 18-Jul-2018 CET/CEST ...
DGAP-News: LION E-Mobility AG / Key word(s): Alliance/Product Launch LION E-Mobility AG: LION E-Mobility AG announces marketing strategy for LIGHT Battery 17.07.2018 / 16:07 The issuer is solely responsible for the content of this announcement. 705415 17.07.2018 ...
DGAP-News: EDAG Engineering Group AG / Key word(s): Mergers & Acquisitions EDAG Engineering Group AG: EDAG reaches agreement with Zielpuls on essential parameters of an acquisition 16.07.2018 / 08:30 The issuer is solely responsible for the content of this announcement. 704489 16.07.2018 ...
DGAP-News: LION E-Mobility AG / Key word(s): Change of Personnel/Miscellaneous LION E-Mobility AG: LION E-Mobility AG appoints Thomas Hetmann as new CFO 13.07.2018 / 10:15 The issuer is solely responsible for the content of this announcement. 704343 13.07.2018 ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results BB Biotech AG reports preliminary results for 1H 2018 12-Jul-2018 / 18:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 703867 12-Jul-2018 CET/CEST ...
DGAP-Ad-hoc: EDAG Engineering Group AG / Key word(s): Change in Forecast/Preliminary Results EDAG Engineering Group AG: Increase of revenue guidance after strong H1 12-Jul-2018 / 11:12 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible ...
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Miscellaneous BB Biotech AG admitted to the SMIM and SPI Index 09-Jul-2018 / 18:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 702815 09-Jul-2018 CET/CEST ...
DGAP-News: EDAG Engineering Group AG / Key word(s): Financing EDAG Engineering Group AG: EDAG places promissory note loan in the amount of 120 million Euros 09.07.2018 / 08:30 The issuer is solely responsible for the content of this announcement. 702259 09.07.2018 ...
DGAP-Ad-hoc: Mars One Ventures AG / Key word(s): Investment Mars One Ventures AG signs EUR12m funding agreement with Phoenix Enterprises AG 06-Jul-2018 / 09:10 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this ...
DGAP-News: LION E-Mobility AG / Key word(s): AGM/EGM/Miscellaneous LION E-Mobility AG: Information on the results of the Annual General Meeting 2018 03.07.2018 / 09:10 The issuer is solely responsible for the content of this announcement. 700813 03.07.2018 ...
Munich (ots/PRNewswire) - - Sub-analysis presented from ENGAGE AF-TIMI 48, the longest single comparative global trial of a non-vitamin K oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation (NVAF) to date - Results showed a reduction in both spontaneous and traumatic intracranial haemorrhage ...
Munich (ots/PRNewswire) - For EU media only - not for US journalists - Hokusai-VTE CANCER study is a phase 3b, prospective, randomised, open-label, blind end-point (PROBE) study evaluating edoxaban versus low molecular weight heparin (LMWH) dalteparin in venous thromboembolism (VTE) associated with primarily active ...
Munich (ots/PRNewswire) - - Sub-analysis highlights the protective effect of edoxaban against stroke or systemic embolic events (SEEs) and its superior safety in terms of major bleeding risk compared to warfarin, in non-valvular atrial fibrillation (NVAF) patients at varying levels of stroke risk.[1] - The data is ...